Book contents
- Subfertility, Reproductive Endocrinology and Assisted Reproduction
- Subfertility, Reproductive Endocrinology and Assisted Reproduction
- Copyright page
- Contents
- Contributors
- Chapter 1 The Patient’s Perspective
- Chapter 2 Epidemiology of Infertility
- Chapter 3 Investigation of Male Infertility
- Chapter 4 Female Fertility
- Chapter 5 Unexplained Infertility
- Chapter 6 Overview of Management of Male Infertility
- Chapter 7 Semen Analysis and Sperm Function Tests
- Chapter 8 Assessment of Fallopian Tube Patency
- Chapter 9 Endometriosis
- Chapter 10 Congenital Uterine Abnormalities
- Chapter 11 Fibroids and Fertility
- Chapter 12 Tubal Factor Infertility and Tubal Surgery
- Chapter 13 Fertility and the Hypogonadal Male
- Chapter 14 Causes and Investigation of Ovarian Infertility
- Chapter 15 Ovulation Induction for Anovulatory Infertility
- Chapter 16 The Role of Regulation in Reproductive Medicine
- Chapter 17 Common Stimulation Regimens in Assisted Reproductive Technology
- Chapter 18 Oocyte Retrieval and Embryo Transfer
- Chapter 19 Gamete Preparation and Embryo Culture
- Chapter 20 Single Embryo Transfer
- Chapter 21 The Risks of Assisted Reproduction
- Chapter 22 Gamete and Embryo Cryopreservation
- Chapter 23 Quality Management in Reproductive Medicine
- Chapter 24 Early Pregnancy
- Chapter 25 Evaluation and Management of Recurrent Miscarriage
- Chapter 26 Sperm Retrieval
- Chapter 27 Preimplantation Genetic Testing
- Chapter 28 Adjuvant Treatment and Alternative Therapies to Improve Fertility
- Chapter 29 Male Fertility Preservation
- Chapter 30 Female Fertility Preservation
- Chapter 31 Donor Recruitment
- Chapter 32 Gamete Donation
- Chapter 33 Training Opportunities in Reproductive Medicine
- Index
- References
Chapter 15 - Ovulation Induction for Anovulatory Infertility
Published online by Cambridge University Press: 03 June 2019
- Subfertility, Reproductive Endocrinology and Assisted Reproduction
- Subfertility, Reproductive Endocrinology and Assisted Reproduction
- Copyright page
- Contents
- Contributors
- Chapter 1 The Patient’s Perspective
- Chapter 2 Epidemiology of Infertility
- Chapter 3 Investigation of Male Infertility
- Chapter 4 Female Fertility
- Chapter 5 Unexplained Infertility
- Chapter 6 Overview of Management of Male Infertility
- Chapter 7 Semen Analysis and Sperm Function Tests
- Chapter 8 Assessment of Fallopian Tube Patency
- Chapter 9 Endometriosis
- Chapter 10 Congenital Uterine Abnormalities
- Chapter 11 Fibroids and Fertility
- Chapter 12 Tubal Factor Infertility and Tubal Surgery
- Chapter 13 Fertility and the Hypogonadal Male
- Chapter 14 Causes and Investigation of Ovarian Infertility
- Chapter 15 Ovulation Induction for Anovulatory Infertility
- Chapter 16 The Role of Regulation in Reproductive Medicine
- Chapter 17 Common Stimulation Regimens in Assisted Reproductive Technology
- Chapter 18 Oocyte Retrieval and Embryo Transfer
- Chapter 19 Gamete Preparation and Embryo Culture
- Chapter 20 Single Embryo Transfer
- Chapter 21 The Risks of Assisted Reproduction
- Chapter 22 Gamete and Embryo Cryopreservation
- Chapter 23 Quality Management in Reproductive Medicine
- Chapter 24 Early Pregnancy
- Chapter 25 Evaluation and Management of Recurrent Miscarriage
- Chapter 26 Sperm Retrieval
- Chapter 27 Preimplantation Genetic Testing
- Chapter 28 Adjuvant Treatment and Alternative Therapies to Improve Fertility
- Chapter 29 Male Fertility Preservation
- Chapter 30 Female Fertility Preservation
- Chapter 31 Donor Recruitment
- Chapter 32 Gamete Donation
- Chapter 33 Training Opportunities in Reproductive Medicine
- Index
- References
Summary
Folic acid should be taken at a daily dose of 400 mcg or, in those who are obese, 5 mg. There is debate about the restriction of fertility treatment to women who are overweight, although there is no doubt that obesity has a significant adverse impact on reproductive outcome. It influences not only the chance of conception but also the response to fertility treatment and increases the risk of miscarriage, congenital anomalies and pregnancy complications [1]. The British Fertility Society guidance suggests that treatment should be deferred until the BMI is less than 35 kg/m2, although in those with more time (e.g. less than 37 years, normal ovarian reserve) a weight reduction to a BMI of less than 30 kg/m2 is preferable [2]. Even a moderate weight loss of 5–10% of body weight can be sufficient to restore fertility and improve metabolic parameters.
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2019